Segment Reporting (Tables)

6 Months Ended

Jul. 04, 2025

Schedule of Segment and Consolidated Net Income, Including Significant Segment Expenses

The segment and consolidated net income, including significant segment expenses were as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Revenues	$	568,261	$	637,178	$	1,123,708	$	1,062,404
Less:
Cost of goods sold	19,470		17,667		38,642		38,923
Drug discovery	21,357		25,096		39,610		47,586
Development	134,159		146,234		287,376		319,121
Selling, general, and administrative	112,931		115,839		233,706		214,602
Other segment items(1)	66,718		56,755		124,134		137,212
Interest income	(16,789)		(17,258)		(35,865)		(37,152)
Provision for income taxes	45,567		66,729		91,641		78,679
Segment and consolidated net income	$	184,848	$	226,116	$	344,464	$	263,433

_________________

(1) Other segment items include stock-based compensation, restructuring expenses, other research and development expenses including the allocation of general corporate costs to research and development services and development cost reimbursements in connection with certain of our collaboration arrangements, and other income (expenses), net.